Home | Contact | Directions
Bookmark and Share

Newsroom

Constellation Pharmaceuticals, Inc. To Present At The Epigenetics: Cancer and Beyond Symposium

Posted in Constellation in the News, Newsroom

CAMBRIDGE, Massachusetts, April 20, 2016 – Constellation Pharmaceuticals, Inc., a leader in the rapidly expanding field of epigenetics, today announced that Patrick Trojer, PhD, Vice President of Research, will present at the Epigenetics: Cancer and Beyond Symposium on Thursday, April 28, …

Read more »

Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes

Posted in Constellation in the News, Newsroom

Our paper “Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes” is now available in the AACR Journal of Cancer Research.

http://cancerres.aacrjournals.org/content/76/7/1975.abstract…

Read more »

Constellation Pharmaceuticals, Inc. To Present At The 15th Annual Needham Healthcare Conference

Posted in Constellation in the News, Newsroom

CAMBRIDGE, Massachusetts, April 4, 2016 – Constellation Pharmaceuticals, Inc., a leader in the rapidly expanding field of epigenetics, today announced that Keith Dionne, PhD, President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference on Tuesday, …

Read more »

Constellation’s CEO Keith Dionne to present at 34th Annual J.P. Morgan Healthcare Conference in San Francisco. 7:30 am on January 11th 2016

Posted in Newsroom

CAMBRIDGE, January 5, 2016.  Constellation’s CEO, Keith Dionne, will be presenting a corporate update at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 7:30 a.m. Pacific at the Westin St. Francis Hotel in San Francisco. The

Read more »

Constellation Pharmaceuticals, Inc. Raises $55 Million in Mezzanine Financing

Posted in Newsroom

Funding Supports Advancement of Pipeline and Epigenetics Platform

CAMBRIDGE, Massachusetts, December 9, 2015 – Constellation Pharmaceuticals, Inc., a leader in the rapidly expanding field of epigenetics, today announced the successful completion of a $55 million mezzanine round of financing. The …

Read more »

Constellation Pharmaceuticals Initiates Clinical Development of CPI-1205, a Novel Inhibitor of EZH2, in Patients with Lymphoma

Posted in Constellation in the News, Newsroom

Second Constellation Pipeline Program to Enter the Clinic

CAMBRIDGE, Mass. –April 28, 2015 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of chromatin biology, today announced that it has initiated a Phase 1 clinical trial of …

Read more »

Development of methyl isoxazoleazepines as inhibitors of BET

Posted in Constellation in the News, Newsroom

Our paper “Development of methyl isoxazoleazepines as inhibitors of BET” is now available in Bioorganic & Medicinal Chemistry Letters.

View full paper here.

 …

Read more »

The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors

Posted in Constellation in the News, Newsroom

This paper, by Dr. Eugenia Xu and colleagues from the Sackler Foundation and Robert Wood Johnson Medical School and scientists from Constellation Pharmaceuticals, is now available in the open-access journal Cell Death and Disease.

View full paper here

Read more »

Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

Posted in Constellation in the News, Newsroom

In this paper, Dr. Gael Roué and his colleagues at the IDIBAPS in Barcelona and scientists from Constellation Pharmaceuticals presented evidence of a synergistic anti-tumor activity of lenalidomide in combination with a BET inhibitor in bortezomib-resistant mantle cell lymphoma cell …

Read more »

EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation

Posted in Constellation in the News, Newsroom

Our paper “EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation” is now available in Cell Press, Chemistry and Biology.

View full paper here

Read more »

next »